TREMFYA guselkumab (rch) 100 mg solution for injection pre-filled pen (One-Press (R) patient controlled injector) Australien - Englisch - Department of Health (Therapeutic Goods Administration)

tremfya guselkumab (rch) 100 mg solution for injection pre-filled pen (one-press (r) patient controlled injector)

janssen-cilag pty ltd - guselkumab, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; histidine; sucrose; polysorbate 80; histidine hydrochloride monohydrate - plaque psoriasis,tremfya is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,psoriatic arthritis,tremfya is indicated for the treatment of adult patients with active psoriatic arthritis, who have had an inadequate response to, or are intolerant to prior dmard therapy.

TREMFYA guselkumab 100 mg solution for injection, prefilled syringe Australien - Englisch - Department of Health (Therapeutic Goods Administration)

tremfya guselkumab 100 mg solution for injection, prefilled syringe

janssen-cilag pty ltd - guselkumab, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; sucrose; histidine hydrochloride monohydrate; histidine; polysorbate 80 - plaque psoriasis,tremfya is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,psoriatic arthritis,tremfya is indicated for the treatment of adult patients with active psoriatic arthritis, who have had an inadequate response to, or are intolerant to prior dmard therapy.

ESMOLOL NORIDEM esmolol hydrochloride 100 mg/10 mL solution for injection ampoule Australien - Englisch - Department of Health (Therapeutic Goods Administration)

esmolol noridem esmolol hydrochloride 100 mg/10 ml solution for injection ampoule

interpharma pty ltd - esmolol hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium acetate trihydrate; glacial acetic acid; hydrochloric acid; water for injections; sodium hydroxide; sodium chloride - supraventricular tachycardia - esmolol noridem is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol noridem is also indicated in non-compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. esmolol noridem is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

ESMOLOL JUNO esmolol hydrochloride100 mg/10 mL solution for injection vial Australien - Englisch - Department of Health (Therapeutic Goods Administration)

esmolol juno esmolol hydrochloride100 mg/10 ml solution for injection vial

juno pharmaceuticals pty ltd - esmolol hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; sodium chloride; glacial acetic acid; sodium acetate trihydrate - supraventricular tachycardia,esmolol juno is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol juno is also indicated in non compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. esmolol juno is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

DEXAMETHASONE JUNO dexamethasone phosphate (as dexamethasone sodium phosphate) 8 mg/2 mL solution for injection ampoule Australien - Englisch - Department of Health (Therapeutic Goods Administration)

dexamethasone juno dexamethasone phosphate (as dexamethasone sodium phosphate) 8 mg/2 ml solution for injection ampoule

juno pharmaceuticals pty ltd - dexamethasone sodium phosphate, quantity: 8.74 mg (equivalent: dexamethasone phosphate, qty 8 mg) - injection, solution - excipient ingredients: sodium citrate; water for injections; disodium edetate; sodium hydroxide; creatinine - replacement therapy - adrenocortical insufficiency,dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in:,? acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy;,? relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available;,? primary and secondary adrenocortical insufficiency.,disease therapy,dexamethasone is indicated for therapy of the following diseases:,collagen diseases: systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, giant cell arteritis, adjunctive therapy for short-term administration during an acute episode or exacerbation, acute rheumatic carditis ? during an exacerbation or as maintenance therapy.,pulmonary disorders: status asthmaticus, chronic asthma, sarcoidosis, respiratory insufficiency.,blood disorders: leukaemia, idiopathic thrombocytopaenic purpura in adults, acquired (autoimmune) haemolytic anaemia.,rheumatic diseases: rheumatoid arthritis, osteoarthritis, adjunctive therapy for short-term administration during an acute episode or exacerbation of rheumatoid arthritis or osteoarthritis.,skin diseases: psoriasis, erythema multiforme, pemphigus, neutrophilic dermatitis, localised neurodermatitis, exfoliative dermatitis, sarcoidosis of skin, severe seborrhoeic dermatitis, contact dermatitis.,gastrointestinal disorders: ulcerative colitis, regional enteritis.,oedema: cerebral oedema associated with primary or metastatic brain tumours, neurosurgery or stroke, oedema associated with acute non-infectious laryngospasm (or laryngitis).,eye disorders: allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, chorioretinitis, optic neuritis, anterior ischaemic optic neuropathy.,neoplastic states: cerebral neoplasms, hypercalcaemia associated with cancer, leukaemias and lymphomas in adults, acute leukaemia in children.,endocrine disorders: adrenal insufficiency.,preoperative and postoperative support,dexamethasone may be used in any surgical procedure when the adrenocortical reserve is doubtful. this includes the treatment of shock due to excessive blood loss during surgery.,shock,dexamethasone may be used as an adjunct in the treatment of shock. dexamethasone should not be used as a substitute for normal shock therapy.

DEXAMETHASONE JUNO dexamethasone phosphate (as dexamethasone sodium phosphate) 4 mg/1 mL solution for injection ampoule Australien - Englisch - Department of Health (Therapeutic Goods Administration)

dexamethasone juno dexamethasone phosphate (as dexamethasone sodium phosphate) 4 mg/1 ml solution for injection ampoule

juno pharmaceuticals pty ltd - dexamethasone sodium phosphate, quantity: 4.37 mg (equivalent: dexamethasone phosphate, qty 4 mg) - injection, solution - excipient ingredients: disodium edetate; water for injections; sodium citrate; creatinine; sodium hydroxide - replacement therapy - adrenocortical insufficiency,dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in:,? acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy;,? relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available;,? primary and secondary adrenocortical insufficiency.,disease therapy,dexamethasone is indicated for therapy of the following diseases:,collagen diseases: systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, giant cell arteritis, adjunctive therapy for short-term administration during an acute episode or exacerbation, acute rheumatic carditis ? during an exacerbation or as maintenance therapy.,pulmonary disorders: status asthmaticus, chronic asthma, sarcoidosis, respiratory insufficiency.,blood disorders: leukaemia, idiopathic thrombocytopaenic purpura in adults, acquired (autoimmune) haemolytic anaemia.,rheumatic diseases: rheumatoid arthritis, osteoarthritis, adjunctive therapy for short-term administration during an acute episode or exacerbation of rheumatoid arthritis or osteoarthritis.,skin diseases: psoriasis, erythema multiforme, pemphigus, neutrophilic dermatitis, localised neurodermatitis, exfoliative dermatitis, sarcoidosis of skin, severe seborrhoeic dermatitis, contact dermatitis.,gastrointestinal disorders: ulcerative colitis, regional enteritis.,oedema: cerebral oedema associated with primary or metastatic brain tumours, neurosurgery or stroke, oedema associated with acute non-infectious laryngospasm (or laryngitis).,eye disorders: allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, chorioretinitis, optic neuritis, anterior ischaemic optic neuropathy.,neoplastic states: cerebral neoplasms, hypercalcaemia associated with cancer, leukaemias and lymphomas in adults, acute leukaemia in children.,endocrine disorders: adrenal insufficiency.,preoperative and postoperative support,dexamethasone may be used in any surgical procedure when the adrenocortical reserve is doubtful. this includes the treatment of shock due to excessive blood loss during surgery.,shock,dexamethasone may be used as an adjunct in the treatment of shock. dexamethasone should not be used as a substitute for normal shock therapy.

ESMOLOL HYDROCHLORIDE MEDSURGE esmolol hydrochloride 100 mg/10 mL solution for injection vial Australien - Englisch - Department of Health (Therapeutic Goods Administration)

esmolol hydrochloride medsurge esmolol hydrochloride 100 mg/10 ml solution for injection vial

medsurge pharma pty ltd - esmolol hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate trihydrate; sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - esmolol hydrochloride medsurge is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. esmolol hydrochloride medsurge is also indicated in non-compensatory sinus tachycardia where, in the physician?s judgement, the rapid heart rate requires specific intervention. esmolol hydrochloride medsurge is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.

4FARMERS TRIADIMENOL 150 C FLOWABLE FUNGICIDE/INSECTICIDE SEED TREATMENT Australien - Englisch - APVMA (Australian Pesticides and Veterinary Medicines Authority)

4farmers triadimenol 150 c flowable fungicide/insecticide seed treatment

4 farmers australia pty ltd - cypermethrin; triadimenol - suspension concentrate - cypermethrin pyrethroid active 4.0 g/l; triadimenol triazole active 150.0 g/l - mixed function seed treat - barley | oats | wheat - bunt | covered smut (bunt) - tilletia spp. | flag smut on cereal | granary weevil | indian meal moth | leaf scald - suppression | lesser grain borer | loose smut - ustilago avenae | powdery mildew of seedling infection | rice weevil | rust-red flour beetle | sawtoothed grain beetle | speckled leaf blotch - suppression | stripe rust - suppression | tropical warehouse moth | bunt | common bunt | grain borer | seedborne flag smut | seedling infections | soilborne flag smut | trilletia tritici | ustilago nuda (tritici)

AC CAPRICE 570 EC SELECTIVE HERBICIDE Australien - Englisch - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ac caprice 570 ec selective herbicide

axichem pty ltd - mcpa present as the 2-ethyl hexyl ester - emulsifiable concentrate - mcpa present as the 2-ethyl hexyl ester phenoxy acids-mcpa-ester active 570.0 g/l - herbicide

AC ESCORT 680 HERBICIDE Australien - Englisch - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ac escort 680 herbicide

axichem pty ltd - 2,4-d present as the 2-ethylhexyl ester - emulsifiable concentrate - 2,4-d present as the 2-ethylhexyl ester phenoxy acids-2,4-d-ester active 680.0 g/l - herbicide